The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Downregulation of GLP-1 and GIP Receptor Expression by Hyperglycemia
Abstract
Stimulation of insulin secretion by the incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) has been found to be diminished in type 2 diabetes. We hypothesized that this impairment is due to a defect at the receptor level induced by the diabetic state, particularly hyperglycemia. Gene expression of incretin receptors, GLP-1R and GIPR, were significantly decreased in islets of 90% pancreatectomized (Px) hyperglycemic rats, with recovery when glucose levels were normalized by phlorizin. Perifused islets isolated from hyperglycemic Px rats showed reduced insulin responses to GLP-1 and GIP. To examine the acute effect of hyperglycemia on incretin receptor expression, a hyperglycemic clamp study was performed for 96 h with reduction of GLP-1 receptor expression but increase in GIP receptor expression. Similar findings were found when islets were cultured at high glucose concentrations for 48 h. The reduction of GLP-1 receptor expression by high glucose was prevented by dominant-negative protein kinase C (PKC)α overexpression, whereas GLP-1 receptor expression was reduced with wild-type PKCα overexpression. Taken together, GLP-1 and GIP receptor expression is decreased with chronic hyperglycemia, and this decrease likely contributes to the impaired incretin effects found in diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A simplified system for generating recombinant adenoviruses
He, T.-C., Zhou, S., da Costa, L. T., Yu, J., Kinzler, K. W., & Vogelstein, B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.5.2509 · Cited by 3,206
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Self-citationFive stages of evolving beta-cell dysfunction during progression to diabetes
Weir, G. C., & Bonner-Weir, S. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s16 · Cited by 1,126
Self-citationMojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882
Self-citationDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans
Holst, J. J., & Gromada, J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00545.2003 · Cited by 611
The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582
Cited by
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Pancreatic β-Cell Electrical Activity and Insulin Secretion: Of Mice and Men
Rorsman, P., & Ashcroft, F. M. (2018) · Physiological Reviews · doi:10.1152/physrev.00008.2017 · Cited by 793
Nauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00482-9 · Cited by 503
Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs
Artasensi, A., Pedretti, A., Vistoli, G., & Fumagalli, L. (2020) · Molecules · doi:10.3390/molecules25081987 · Cited by 494
Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
Deacon, C. F. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00080 · Cited by 428
Muscelli, E., Mari, A., Casolaro, A., Camastra, S., Seghieri, G., Gastaldelli, A., Holst, J. J., & Ferrannini, E. (2008) · Diabetes · doi:10.2337/db07-1315 · Cited by 409
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Frias, J. P., Bastyr, E. J., Vignati, L., Tschöp, M. H., Schmitt, C., Owen, K., Christensen, R. H., & DiMarchi, R. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.011 · Cited by 321
Parker, H. E., Habib, A. M., Rogers, G. J., Gribble, F. M., & Reimann, F. (2009) · Diabetologia · doi:10.1007/s00125-008-1202-x · Cited by 324
Nauck, M. A. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.002 · Cited by 295
Grasset, E., Puel, A., Charpentier, J., Collet, X., Christensen, J. E., Tercé, F., & Burcelin, R. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.013 · Cited by 281
Incretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls
Drucker, D. J. (2013) · Diabetes · doi:10.2337/db13-0822 · Cited by 272
Shu, L., Matveyenko, A. V., Kerr-Conte, J., Cho, J.-H., McIntosh, C. H. S., & Maedler, K. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp178 · Cited by 270
Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2013) · Diabetologia · doi:10.1007/s00125-013-2841-0 · Cited by 251
The incretin system in healthy humans: The role of GIP and GLP-1
Holst, J. J. (2019) · Metabolism · doi:10.1016/j.metabol.2019.04.014 · Cited by 248
Meier, J. J., & Nauck, M. A. (2010) · Diabetes · doi:10.2337/db09-1899 · Cited by 215
Diabetes and beta cell function: from mechanisms to evaluation and clinical implications
Cernea, S., & Dobreanu, M. (2013) · Biochemia Medica · doi:10.11613/bm.2013.033 · Cited by 203
Mentis, N., Vardarli, I., Köthe, L. D., Holst, J. J., Deacon, C. F., Theodorakis, M., Meier, J. J., & Nauck, M. A. (2011) · Diabetes · doi:10.2337/db10-1332 · Cited by 197
Incretin hormones and type 2 diabetes
Nauck, M. A., & Müller, T. D. (2023) · Diabetologia · doi:10.1007/s00125-023-05956-x · Cited by 190
Reappraisal of GIP Pharmacology for Metabolic Diseases
Finan, B., Müller, T. D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R. D., & Tschöp, M. H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.005 · Cited by 180
Liu, L., Liu, J., Wong, W. T., Tian, X. Y., Lau, C. W., Wang, Y.-X., Xu, G., Pu, Y., Zhu, Z., Xu, A., et al. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.195115 · Cited by 179
Self-citationGlucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171
Solomon, T. P., Haus, J. M., Kelly, K. R., Cook, M. D., Filion, J., Rocco, M., Kashyap, S. R., Watanabe, R. M., Barkoukis, H., & Kirwan, J. P. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2010.29771 · Cited by 165
Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes
Calanna, S., Christensen, M., Holst, J. J., Laferrère, B., Gluud, L. L., Vilsbøll, T., & Knop, F. K. (2013) · Diabetes Care · doi:10.2337/dc13-0465 · Cited by 158
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00117 · Cited by 153
Targeted pharmacological therapy restores β-cell function for diabetes remission
Sachs, S., Bastidas-Ponce, A., Tritschler, S., Bakhti, M., Böttcher, A., Sánchez-Garrido, M. A., Tarquis-Medina, M., Kleinert, M., Fischer, K., Jall, S., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0171-3 · Cited by 147
Piteau, S., Olver, A., Kim, S.-J., Winter, K., Pospisilik, J. A., Lynn, F., Manhart, S., Demuth, H.-U., Speck, M., Pederson, R. A., et al. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.115 · Cited by 130
Nakatani, Y., Maeda, M., Matsumura, M., Shimizu, R., Banba, N., Aso, Y., Yasu, T., & Harasawa, H. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.05.009 · Cited by 126
Nogi, Y., Nagashima, M., Terasaki, M., Nohtomi, K., Watanabe, T., & Hirano, T. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035683 · Cited by 96
Green, C. J., Henriksen, T. I., Pedersen, B. K., & Solomon, T. P. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044284 · Cited by 80
Pulsatility of insulin release – a clinically important phenomenon
Hellman, B. (2009) · Upsala Journal of Medical Sciences · doi:10.3109/03009730903366075 · Cited by 77
GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease–A Systematic Review
Mori, Y., Matsui, T., Hirano, T., & Yamagishi, S.-I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041509 · Cited by 60
Delghingaro-Augusto, V., Nolan, C. J., Gupta, D., Jetton, T. L., Latour, M. G., Peshavaria, M., Madiraju, S. R. M., Joly, É., Peyot, M.-L., Prentki, M., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1317-8 · Cited by 57
Decreased Hypothalamic Glucagon-Like Peptide-1 Receptor Expression in Type 2 Diabetes Patients
ten Kulve, J. S., van Bloemendaal, L., Balesar, R., IJzerman, R. G., Swaab, D. F., Diamant, M., la Fleur, S. E., & Alkemade, A. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3291 · Cited by 54
Kushima, H., Mori, Y., Koshibu, M., Hiromura, M., Kohashi, K., Terasaki, M., Fukui, T., & Hirano, T. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0603-x · Cited by 48
Zafer, M., Tavaglione, F., Romero‐Gómez, M., & Loomba, R. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70196 · Cited by 47
Besch, G., Perrotti, A., Mauny, F., Puyraveau, M., Baltres, M., Flicoteaux, G., Salomon du Mont, L., Barrucand, B., Samain, E., Chocron, S., et al. (2017) · Anesthesiology · doi:10.1097/aln.0000000000001838 · Cited by 38
GLP1R and GIPR expression and signaling in pancreatic alpha cells, beta cells and delta cells
Shilleh, A. H., Viloria, K., Broichhagen, J., Campbell, J. E., & Hodson, D. J. (2024) · Peptides · doi:10.1016/j.peptides.2024.171179 · Cited by 39
Ma, B., Wang, X., Ren, H., Li, Y., Zhang, H., Yang, M., & Li, J. (2023) · BMC Cancer · doi:10.1186/s12885-023-11077-w · Cited by 36
Genetic disruption of the Gipr in Apoe−/− mice promotes atherosclerosis
Pujadas, G., Baggio, L. L., Kaur, K. D., McLean, B. A., Cao, X., & Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101586 · Cited by 34
Glucagon‐like peptide‐1: modulator of β ‐cell dysfunction and death
Rondas, D., D'Hertog, W., Overbergh, L., & Mathieu, C. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12165 · Cited by 32
Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors
Deacon, C. F. (2020) · Peptides · doi:10.1016/j.peptides.2019.170196 · Cited by 31
GLP-1-Based Strategies: A Physiological Analysis of Differential Mode of Action
Burcelin, R., Gourdy, P., & Dalle, S. (2014) · Physiology · doi:10.1152/physiol.00009.2013 · Cited by 26
Lee, S. (2026) · Toxicology Mechanisms and Methods · doi:10.1080/15376516.2025.2584495 · Cited by 8
Metadata
- Authors
- Xu, G., Kaneto, H., Laybutt, D. R., Duvivier-Kali, V. F., Trivedi, N., Suzuma, K., King, G. L., Weir, G. C., & Bonner-Weir, S.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2007-06-01
- Volume
- 56
- Issue
- 6
- Pages
- 1551-1558
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2411384485
- Cited by
- 377
- References
- 39
- FWCI
- 16.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.